hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 23:19:32 - browse：73

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： South Korea throws huge K

entertainment

WSS

A preacher's new calling: Diversifying neuroscience research

Friends ask where James Watson's attitudes about race came from

Profiling embryos to choose those with higher IQs is almost a reality

NIH trials fail to test meaningful long Covid therapies, experts say

American woman, child freed after being kidnapped in Haiti last month

Methadone doses haven’t kept up in the age of fentanyl

focus

hotspot

hotspot

Guidelines to prevent youth baseball injuries need more muscle

A preacher's new calling: Diversifying neuroscience research

Moonlake's readout produced a cash windfall. Risks remain

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

The cancer drug shortage isn’t new — and neither are the solutions

How to use technology to prevent future drug shortages

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NIH trials fail to test meaningful long Covid therapies, experts say

Jerome Adams on the need for new antivirals for Covid

NIH trials fail to test meaningful long Covid therapies, experts say

leisure time

Emergent cuts jobs, executive role in business shake

Physician assistants need a new name. Here's what it should be

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Medicare Advantage coverage denials need scrutiny, senators say

Police still searching for prisoner who escaped from NYC hospital

Emergent cuts jobs, executive role in business shake

hotspot

knowledge

entertainment

Wikipedia